Advanced endoscopic imaging in gastric neoplasia and preneoplasia

Jonathan W J Lee,1 Lee Guan Lim,2 Khay Guan Yeoh,1,3
part of the Singapore Gastric Cancer Consortium

ABSTRACT
Conventional white light endoscopy remains the current standard in routine clinical practice for early detection of gastric cancer. However, it may not accurately diagnose preneoplastic gastric lesions. The technological advancements in the field of endoscopic imaging for gastric lesions are fast growing. This article reviews currently available advanced endoscopic imaging modalities, in particular chromoendoscopy, narrow band imaging and confocal laser endomicroscopy, and their corresponding evidence shown to improve diagnosis of preneoplastic gastric lesions. Raman spectrometry and polarimetry are also introduced as promising emerging technologies.

INTRODUCTION
Gastric cancer is the third leading cause of cancer deaths worldwide.1,2 To decrease mortality, early detection and accurate diagnosis of gastric cancer through endoscopy is critical. In recent years, despite numerous advancements in endoscopic imaging, conventional white light endoscopy (WLE) remains the fundamental step for detection and characterisation of gastric lesions in clinical practice. However, conventional WLE may not accurately diagnose preneoplastic gastric lesions. Hence, the European Society of Gastrointestinal Endoscopy (ESGE)3 has recommended the use of image-enhanced endoscopy, including magnification chromoendoscopy and narrow band imaging to improve the diagnosis of gastric preneoplastic conditions. This review aims to highlight the available image-enhancing endoscopic modalities to aid diagnosis of gastric adenocarcinoma and preneoplastic gastric lesions, which include gastric intestinal metaplasia and dysplasia.

WHITE LIGHT ENDOSCOPY (WLE)
Atkins and Benedict4 first highlighted poor correlation between WLE findings and histopathological analysis. Their conclusion was further substantiated by subsequent studies4 demonstrating that conventional WLE cannot reliably diagnosis Helicobacter pylori gastritis3,6 or intestinal metaplasia.7

However, recent evidence for WLE to identify gastric preneoplastic lesions remain promising: Panteris et al.8 demonstrated that real-time high-definition WLE (HD-WLE), during routine endoscopy practice, had an accuracy of 88% in identifying intestinal metaplasia; with sensitivity of 74.6%, specificity of 94.2%, positive predictive value of 82.5% and negative predictive value of 90.1%. In their study, all clinically significant type III intestinal metaplasia and dysplastic lesions were successfully detected using HD-WLE, whereas gastric lesions not picked up by HD-WLE were either mild grade or with no dysplasia. Furthermore, Xiouchakis et al.9 also demonstrated that the use of WLE with adherence to the updated Sydney biopsy protocol (WLE-USP) had greater accuracy compared with narrow band imaging-targeted biopsies (NBI-TB) in detecting premalignant lesions; whereby accuracy for a diagnosis of atrophy and intestinal metaplasia were 93% and 90% for WLE-USP as compared with 82% and 80% for NBI-TB.

Clinical studies regarding the application of WLE for the diagnosis of gastric cancer are few; a meta-analysis of four studies comprising 433 patients and 527 lesions had a pooled sensitivity of 0.48 and sensitivity of 0.67.10 The yield of WLE to diagnose small (<10 mm) depressed gastric mucosal cancer is limited, with one multicentre trial of 176 patients demonstrating only a sensitivity of 40% and specificity of 67.9%.11 However, WLE still remains a valid screening tool for gastric cancer, whereby a larger prospective multicentre study involving 579 patients, showed no statistical difference in gastric cancer detection rates between high-definition WLE (7/286, 2.4%) and NBI (3/293, 1%).12

CONVENTIONAL CHROMOENDOSCOPY (CE)
Conventional CE incorporates topical application of dyes during WLE. An externally
validated classification using CE was previously proposed by Dinis-Ribeiro et al.\textsuperscript{13,14} whereby CE with methylene blue, particularly with magnification, improves identification of gastric lesions. CE with other dyes,\textsuperscript{15–17} such as indigo carmine, acetic acid and haematoxylin, have also been shown to accurately differentiate between normal gastric mucosa and dysplastic or malignant gastric lesions.

Zhao et al.\textsuperscript{18}’s meta-analysis of seven prospective studies, comprising a total of 429 patients and 465 lesions, showed that CE improves the detection of early gastric cancer (<0.01) and premalignant gastric lesions (<0.01) compared with standard WLE. The pooled sensitivity, specificity and area under curve (AUC) of CE were 0.90 (95% CI 0.87 to 0.92), 0.82 (95% CI 0.79 to 0.86) and 0.95, respectively. Majority of the studies used indigo carmine (72.4%) instead of methylene blue (28.6%). However, the meta-analysis did not include a subanalysis comparing the application of different staining dyes. It is postulated indigo carmine is more frequently used, because indigo carmine is a non-absorptive contrast stain, whereas methylene blue has shown to be absorbed by oesophageal cells\textsuperscript{19} and colonocytes,\textsuperscript{20} thereby inducing cellular DNA damage on exposure to white light.

**AUTOFLUORESCENCE IMAGING (AFI)**

AFI is an imaging method, applied during real-time endoscopy, dependent on the fluorescent properties of gastric mucosal particles, such as collagen, flavins and porphyrins, to differentiate between various gastric mucosa subtypes.

The diagnostic utility of AFI in the stomach is confounded by inconsistent autofluorescence patterns and conflicting results in different studies. AFI, compared with WLE, was found to be less sensitive (64% vs 74%, p=0.79) and specific (49% vs 83%, p=0.05), in detecting gastric neoplastic lesions.\textsuperscript{21} Using per-lesion analysis, AFI is also associated with higher false positive rate for gastric lesions, with a specificity of 24% as compared with WLE (84%).\textsuperscript{22}

On the other hand, Kato et al.\textsuperscript{23} demonstrated an increase in gastric neoplasia identification from 18% (WLE) to 56% (WLE+AFI) by adding AFI to WLE during routine endoscopy. More subjects with intestinal metaplasia were also identified using AFI-NBI compared with WLE;\textsuperscript{23} whereby 68% with intestinal metaplasia (26/38) were correctly identified by AFI-NBI (sensitivity 68%, specificity 23%) compared with 34% (13/38) by WLE (sensitivity 34%, specificity 65%). Imaeda et al.\textsuperscript{24} further demonstrated utility of AFI for detecting additional gastric lesions in patients with superficial gastric neoplasia postendoscopic submucosal dissection, whereby five gastric neoplasia missed by WLE were all detected by AFI.

Owing to the conflicting data, the role of AFI in detecting and diagnosing gastric neoplasia and preneoplasia is unclear, and there is currently inadequate evidence to support its routine use in clinical practice.

**COMPUTED VIRTUAL CHROMOENDOSCOPY**

Application of CE requires additional procedure time and materials. Hence, various sources have introduced numerous user-friendly computed virtual chromoendoscopy techniques to improve visualisation of gastric mucosa tissue and vasculature, without the hassle of additional endoscopic probes or dyes. Such technologies include flexible spectral imaging colour enhancement (FICE) (Fujinon, Fujifilm Medical Co, Saitama, Japan), i-Scan (PENTAX Endoscopy, Tokyo, Japan) and narrow band imaging (NBI) (Olympus Medical Systems Tokyo, Japan).

**FLEXIBLE SPECTRAL IMAGING COLOUR ENHANCEMENT (FICE)**

Kikuste et al.\textsuperscript{25} demonstrated good specificity (87%; 95% CI 79% to 95%) and diagnostic accuracy of 74% (95% CI 0.66 to 0.82%) using FICE endoscopy to detect gastric intestinal metaplasia among 126 patients aged over 50 years. In a study by Pittayanon et al.\textsuperscript{26} magnified FICE demonstrated an overall 85.5% accuracy in detecting intestinal metaplasia among 59 lesions in 45 patients, and the accuracy was higher with findings of light blue crest (95.2%) and long large crest (96.8%) and lower with findings of villous pattern (84.3%).

In a meta-analysis by Kikuste et al.\textsuperscript{27} seven studies were included for analysis; however, due to the insufficient data and varying definitions of neoplastic and preneoplastic definitions for FICE, there were no aggregate scores calculated. However, FICE did produce images with more pronounced colour contrast between malignant lesions and benign surrounding mucosa, compared with standard WLE findings, particularly in Osawa et al.’s\textsuperscript{28} study involving 82 patients with depressed early gastric carcinoma.

**i-Scan**

Qi et al.\textsuperscript{29} compared magnification i-Scan and magnification WLE in identifying type 2–3 gastric mucosal pit pattern, predictive of *Helicobacter* infection, whereby diagnosis was then confirmed by positive rapid urease test and positive histopathology. i-Scan provided better image quality with increased recognition of type 2–3 patterns, compared with magnification WLE, and thus increased accuracy of *Helicobacter* infection diagnosis (accuracy 94% vs 84.5%, sensitivity 95.5% vs 95.5%, specificity 93.5% vs 80.6%, positive predictive value (PPV) 84% vs 63.6%, negative predictive value (NPV) 98.3% vs 98.0%).

A prospective study\textsuperscript{30} of 43 patients demonstrated modest results, whereby magnified i-Scan (with tone and surface enhancement) had a relative low specificity and PPV in diagnosing early gastric neoplasia (sensitivity: 100%; specificity: 77.1%; PPV: 50%; NPV: 100%; likelihood ratio: 4.37). These findings were mirrored by Nishimura et al.\textsuperscript{31} who looked at 10 patients with gastric neoplasia, and found no significant difference (p=0.78).
between the diagnostic accuracy using either WLE (91.7%) or i-Scan (90.8%). Interestingly, in this study, the diagnostic accuracy of tumour size using i-Scan was comparable between novice and experienced endoscopists (65.7% vs 71.1%, p=0.53), whereas it was significantly lower for WLE (41.2% vs 79.5%, p=0.019), which may suggest that i-Scan technology will improve diagnostic accuracy of novice endoscopists.

Owing to the limited data on FICE and i-Scan in the diagnosis of gastric preneoplasia and neoplasia and the absence of well-validated definition for gastric preneoplastic and neoplastic mucosal appearances, there is currently insufficient evidence to substantiate application of FICE and i-Scan in routine clinical practice for the diagnosis of gastric neoplasia and preneoplasia.

**Narrow band imaging (NBI)**

NBI, unlike FICE or i-Scan, is accomplished by optical filtering of white light, and is the most well-published virtual CE modality. It has been found to have good sensitivity and specificity for gastric neoplasia and premalignant gastric lesions. Experienced endoscopists in the Asia Pacific region have recommended magnifying NBI over NBI alone for the detection of gastric cancer.32

NBI has established definitions of gastric neoplastic mucosal patterns: Muto et al33 proposed the Magnifying Endoscopy Simple Diagnostic Algorithm for early gastric cancer (MESDA-G) which focuses on the presence of (1) a demarcation line and (2) irregular microvascular pattern and/or irregular micro-surface pattern for the diagnosis of high-grade dysplasia or early gastric cancer. This approach was built on the vessel plus surface NBI technology; Kaneko et al41 demonstrated that BLI-bright mode is the main highlight of this new technology, which allows for vascular contrast detection from a far view, thereby enabling its application in screening endoscopy; Kaneo et al41 demonstrated that BLI-bright mode compared with NBI had appreciable vascular-mucosal contrast from a significantly further distance (26.8 mm vs 16.4 mm, p=0.03), among 14 patients with gastric adenoma. Of note, six of 14 patients with gastric enhanced detection of gastric lesions. However, Ang et al35 have demonstrated, in a multicentre prospective randomised study involving 579 patients, that NBI detected more focal gastric lesions as compared with high-definition WLE (40.6% vs 29%, p=0.003), as well as a greater proportion of intestinal metaplasia (17.7% vs 7.7%, p<0.001). On a similar note, Tongtawee et al’s36 study of 200 patients demonstrated that NBI also reliably identifies gastric mucosal morphological patterns associated with *H. pylori* infection, which correlated significantly with severity of pathological inflammation grading. A subsequent randomised study39 on 500 subjects noted site-specific biopsy guided by NBI had higher yield of diagnosing *Helicobacter*, as compared with standard WLE biopsy. Findings by Ang and Tongtawee suggest that NBI would be useful to identify sites for high-yield targeted biopsies.

**Blue light imaging (BLI)**

Of worthy mention, BLI is a new computer chromoendoscopy method developed by Fujinon, Fujifilm Medical Company, which uses two lasers; one at wavelength 450 nm, to irradiate white colour illumination, and the other at 410 nm, to enhance surface microvasculature patterns.40 Although there are few prospective studies evaluating the utility of BLI in gastric cancer screening, BLI has been shown to provide excellent endoscopic images to better characterise gastric lesions. The BLI-bright mode is the main highlight of this new technology, which allows for vascular contrast detection from a far view, thereby enabling its application in screening endoscopy; Kaneo et al41 demonstrated that BLI-bright mode compared with NBI had appreciable vascular-mucosal contrast from a significantly further distance (26.8 mm vs 16.4 mm, p=0.03), among 14 patients with gastric adenoma. Of note, six of 14 patients with gastric

---

Figure 1  Light blue crest sign indicating gastric intestinal metaplasia on magnifying NBI. NBI, narrow band imaging.
Confocal Laser Endomicroscopy (CLE)

Confocal laser endomicroscopy (CLE) produces high-magnification histological-like images through measuring the gastric tissue reflectance as a low-power laser is used during endoscopy for illumination. CLE may be applied during real-time endoscopy through either using additional probes or dedicated endoscopes with integrated CLE systems.

A recent meta-analysis performed on CLE and gastric diseases, focused on three domains: (1) detection and diagnosis of polyps and neoplastic lesions (three studies, sensitivity 85% (95% CI 78% to 91%, \( I^2=52.3\% \)), specificity 99% (95% CI 98% to 99%, \( I^2=92.92\% \)), AUC=0.929), (2) gastritis and gastric metaplasia (six studies, sensitivity 94% (95% CI 92% to 96%, \( I^2=54.8\% \)), specificity 95% (CI 92% to 97%, \( I^2=55.6\% \)), AUC=0.983) and (3) \( H. pylori \)-related gastritis (two studies, sensitivity 86% (95% CI 76% to 93%, \( I^2=0\% \)), specificity 93% (95% CI 87% to 97%, \( I^2=2.6\% \)). The pooled analyses demonstrated CLE yields remarkable sensitivity and specificity, in per patient analysis in all three domains. However, the data were based on a limited number of publications.

CLE also allows for targeted biopsies of specific pathological mucosal area, whereby Li et al demonstrated that CLE with targeted biopsies is superior to WLE for the detection and surveillance of gastric intestinal metaplasia. The number of biopsies needed to confirm gastric intestinal metaplasia is a third of that needed with WLE. Furthermore, CLE-guided biopsy boasts a higher diagnostic yield for gastric intestinal metaplasia (63.7%), compared with WLE (15.73%; \( p<0.001 \)).

In our local experience, we compared the diagnostic performance of WLE, AFI, magnified NBI and CLE for the diagnosis of gastric intestinal metaplasia in 20 patients, examining a total of 125 sites. We found that real-time CLE (88% 95% CI 89.8% to 98.2%) had better accuracy compared with conventional WLE (64.8%, 95% CI 55.7% to 73.1%), AFI (68.8%, 95% CI 59.9% to 76.8%) or magnified NBI (84.8%, 95% CI 81% to 93.1%). Off-site review of CLE images further significantly increased the accuracy (95.2%, 95% CI 89.8% to 98.2%, \( p=0.012 \)) of gastric intestinal metaplasia diagnosis (figure 2).

Experience and training greatly affect CLE interpretation. We reported that interpretation of CLE images of gastric intestinal metaplasia by experienced endoscopists was associated with higher sensitivity (95.2% vs 61.9%, \( p=0.039 \)) and higher specificity (93.3% vs 62.2%, \( p<0.001 \)) than interpretation by inexperienced endoscopists. The agreement between interpretation by experienced endoscopists and histology for gastric intestinal metaplasia was also higher than that for inexperienced endoscopists (K=0.864 vs 0.217). Pittayanon et al demonstrated that trainees with no experience in intestinal metaplasia interpretation could achieve high reading accuracy and substantial interobserver agreement after training with 10 sets of CLE video clips. Trainees on achieving high reading accuracy were shown to maintain their high quality of reading skill. Similar findings were noted by Kobayashi et al for CLE diagnosis of gastric cancer, whereby correct WLE interpretation and adequate training in WLE was identified to be the most important factor in achieving highly accurate diagnoses of gastric cancer using CLE.

Emerging Technologies

Endocytoscopy

Endocytoscopy (ECS) is an ultrahigh magnification technology to enable histopathological diagnosis of the gastrointestinal tract, whereby the magnification lens of a conventional endoscope is gradually increased to visualise the gastric mucosa after an application of methylene blue and crystal violet staining. ECS has been shown to have high diagnostic accuracy (sensitivity 86% specificity 100%) for gastric cancer. However, in this study, 10 of the 82 lesions investigated could not be clearly observed by ECS due to poor staining due to viscous mucus or plaque. Sato et al further demonstrated that ECS could differentiate between normal antrum mucosa and preneoplastic changes, whereby they were able to identify four different mucosal patterns in the antrum in a small single-centre pilot study.
| Methodology                          | Manufacturers                                      | Clinical performance                                                                 | Comments                                                                                   |
|-------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Autofluorescence imaging (AFI)      | Olympus Medical Systems; Evis Exera II/III processors | Few studies to demonstrate increase diagnostic yield of gastric cancer and gastric intestinal metaplasia | Inadequate clinical evidence to support routine use of AFI in clinical practice            |
| Fuji intelligent chromo endoscopy (FICE) | Fujinon; Series 500 gastrosopes; VP-4450HD and VP-4400HD processors | No standardised definitions of gastric preneoplastic and neoplastic lesions. Single meta-analysis of seven studies showing more colour contrast compared with WLE alone for gastric cancer and gastric intestinal metaplasia | More clinical evidence required before routine application in clinical practice for gastric lesions |
| i-Scan                              | PENTAX Endoscopy; Series I and 90K gastrosopies, EPK-i5010 processor | No standardised definitions of gastric preneoplastic and neoplastic lesions. Few studies to demonstrate better image quality and recognition of gastric cancer and gastric intestinal metaplasia | More clinical evidence required before routine application in clinical practice for gastric lesions |
| Narrow band imaging (NBI)           | Olympus Medical Systems; Evis Exera II/III processors | Established NBI classification for gastric lesions and neoplasia. Abundant studies and meta-analysis data available to demonstrate accurate characterisation and diagnostic yield of gastric intestinal metaplasia and gastric cancer | Recommended by ESGE to better improve diagnostic yield of gastric cancer and gastric preneoplastic lesions |
| Blue light imaging (BLI)            | Fujinon; VP-4450HD processor                       | Established NBI classification for gastric lesions and neoplasia may be applied. Has two modes (1) contrast mode for magnifying images, (2) bright mode for far view surveillance. Excellent endoscopic images, but few prospective studies | More clinical evidence required before routine application in clinical practice for gastric lesions |
| Confocal laser endomicroscopy (CLE) | 1. Probe-based CLE (Cellvizo confocal miniprobes from Mauna Kea Technologies; GastroFlex UHD probe) 2. Endoscope-mounted CLE (Pentax endoscopy) | Promising results in improving diagnostic yield of gastric cancer, intestinal metaplasia and Helicobacter pylori-related gastritis. Potentiate the need for fewer biopsies to confirm presence of gastric intestinal metaplasia | Adequate training required for accurate CLE diagnosis                                    |
| Endocytoscopy (ECS)                 | Olympus Medical Systems; 1. Probe-based systems (XEC-300, XEC-120) 2. Integrated endoscope systems (XGIF-Q260EC1, XCF-Q260EC1) | Data from limited number of studies available, but promising results in diagnosing cancer and intestinal metaplasia accurately | More clinical evidence required before routine application in clinical practice for gastric lesions |
characterised using magnifying NBI or chromoendoscopy. These enhanced imaged modalities will also direct targeted biopsies. The technological advancements in field of endoscopic imaging for gastric lesions are fast growing. Recognition of the various endoscopic appearances of gastric preneoplastic and neoplastic lesions remains the fundamental first step which allows for subsequent early detection and more accurate characterisation, underlining the importance of training.

CONCLUSIONS

Early detection of gastric preneoplastic lesions allows early treatment and leads to better prognosis. Table 1 provides a summary of the enhanced imaging modalities discussed in this review. Building on Muto et al’s MESDA-G algorithm, we recommend the use of WLE, in particular HD-WLE, for the detection of suspicious gastric lesions. The demarcation line and subsequent microvascular and microsurface pattern should then be

REFERENCES

1. Fock KM. Review article: the epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 2014;40:250–60.
2. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:16–26.
3. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74–94.
4. Atkins L, Benedict EB. Correlation of gross gastroscopic findings with gastroscope biopsy in gastritis. N Engl J Med 1956;254:641–4.
5. Kato T, Yagi N, Kamada T, et al. Diagnosis of Helicobacter pylori infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc 2013;25:508–18.
6. Cho JH, Chang YW, Jang JY, et al. Close observation of gastric mucosal pattern by standard endoscopy can predict Helicobacter pylori infection status. J Gastroenterol Hepatol 2013;28:279–84.
7. Stathopoulos G, Goldberg RD, Blackstone MO. Endoscopic diagnosis of intestinal metaplasia. Gastrointest Endosc 1990;36:544–5.
8. Panteris V, Nikolopoulos S, Lountou A, et al. Diagnostic capabilities of high-definition white light endoscopy for the diagnosis of gastric intestinal metaplasia and correlation with histologic and clinical data. Eur J Gastroenterol Hepatol 2014;26:594–601.
9. Xirouchakis E, Laoudi F, Tsartsali L, et al. Screening for gastric premalignant lesions with narrow band imaging, white light and updated Sydney protocol or both? Dig Dis Sci 2013;58:1084–90.
10. Zhang Q, Wang F, Chen ZY, et al. Comparison of the diagnostic efficacy of white light endoscopy and magnifying endoscopy with narrow band imaging for early gastric cancer: a meta-analysis. Gastric Cancer 2016;19:543–52.
11. Ezeo Y, Muto M, Uedo N, et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011;141:2017–25.e3.
12. Ang TL, Pittayanon R, Lau JY, et al. A multicenter randomized comparison between high-definition white light endoscopy and narrow band imaging for detection of gastric lesions. Eur J Gastroenterol Hepatol 2015;27:1473–8.
13. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc 2003;57:498–504.
14. Areia M, Amaro P, Dinis-Ribeiro M, et al. Estimation of the extent of gastric intestinal metaplasia by methylene blue chromoendoscopy. Eur J Gastroenterol Hepatol 2008;20:939–40.
15. Tanaka K, Toyoda H, Kadowaki S, et al. Surface pattern classification by enhanced-magnification endoscopy for identifying early gastric cancers. *Gastrointest Endosc* 2008;67:430–7.

16. Kono Y, Takenaka R, Kawahara Y, et al. Chromoendoscopy of gastric antrum using an acetic acid indigocarmine mixture. *World J Gastroenterol* 2014;20:5092–7.

17. Mouzika S, Fedoseeva A. Chromoendoscopy with hematoxylin in the classification of gastric lesions. *Gastric Cancer* 2008;11:15–21; discussion 22–3.

18. Zhao Z, Yin Z, Wang S, et al. Meta-analysis: the diagnostic efficacy of chromoendoscopy for early gastric cancer and premalignant gastric lesions. *J Gastroenterol Hepatol* 2016;31:1539–45.

19. Olliver JR, Wild CP, Sahay P, et al. Chromoendoscopy with methylene blue and associated DNA damage in Barrett’s oesophagus. *Lancet* 2003;362:373–4.

20. Davies J, Burke D, Olliver JR, et al. Methylene blue but not indigo carmine causes DNA damage to colonocytes in vitro and in vivo at concentrations used in clinical chromoendoscopy. *Gut* 2007;56:155–6.

21. Kato M, Kaise M, Yonezawa J, et al. Autofluorescence endoscopy versus conventional White light endoscopy for the detection of superficial gastric neoplasia: a prospective comparative study. *Endoscopy* 2007;39:937–41.

22. Kato M. Autofluorescence endoscopy. *Endoscopy* et al. Analysis of the color patterns of early gastric cancer using an autofluorescence imaging video endoscopy system. *Gastric Cancer* 2009;12:219–24.

23. So J, Rajnakova A, Chan YH, et al. Endoscopic tri-modal imaging improves detection of gastric intestinal metaplasia among a high-risk patient population in Singapore. *Dig Dis Sci* 2013;58:3966–75.

24. Imaeda H, Hosoe N, Kashiwagi K, et al. Surveillance using timodal imaging endoscopy after endoscopic submucosal dissection for superficial gastric neoplasia. *World J Gastroenterol* 2014;20:16311–17.

25. Kikuste I, Stima D, Liepinse-Karelie E, et al. The accuracy of flexible spectral imaging color enhancement plus probe-based confocal laser endomicroscopy for gastric intestinal metaplasia: do we still need histology to select individuals at risk for adenocarcinoma? *Eur J Gastroenterol Hepatol* 2014;26:704–9.

26. Pitayanon R, Rerknimitr R, Wisedopas N, et al. Flexible spectral imaging color enhancement plus probe-based confocal laser endomicroscopy for gastric intestinal metaplasia detection. *J Gastroenterol Hepatol* 2013;28:1004–9.

27. Kikuste I, Marques-Pereira R, Monteiro-Soares M, et al. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. *Scand J Gastroenterol* 2013;48:1108–17.

28. Osawa H, Yamamoto H, Miura Y, et al. Diagnosis of extent of early gastric cancer using flexible spectral imaging color enhancement. *World J Gastrointest Endoscopy* 2012;4:356–61.

29. Qi QQ, Zuo XL, Li CQ, et al. High-definition magnifying endoscopy with i-scan in the diagnosis of Helicobacter pylori infection: a pilot study. *J Dig Dis* 2013;14:579–86.

30. Li CQ, Li Y, Zuo XL, et al. Magnified and enhanced computed virtual chromoendoscopy in gastric neoplasia: a feasibility study. *World J Gastroenterol* 2013;19:4221–7.

31. Nishimura J, Nishikawa J, Nakamura M, et al. Magnified and enhanced computed virtual chromoendoscopy in the differentiation of diagnostic gastric intestinal metaplasia: narrow-band imaging with magnifying endoscopy. *Endoscopy* 2006;38:819–24.

32. Tongtawee T, Kaeewipoot S, Kaeewipoot N, et al. Correlation between Gastric Mucosal Morphologic Patterns and Histopathological Severity of Helicobacter pylori Associated Gastritis Using Conventional Narrow Band Imaging *Gastroscopy*. *Biomed Res Int* 2015;2015:808505.

33. Tongtawee T, Dechsularn C, Leeanansaksiri W, et al. Improved detection of Helicobacter pylori infection and premalignant gastric mucosa using “Site Specific Biopsy”: a randomized control clinical trial. *Asian Pac J Cancer Prev* 2015;16:8487–90.

34. Osawa H, Yamamoto H. Present and future status of flexible spectral imaging color enhancement and blue laser imaging technology. *Dig Endosc* 2014;26(Suppl 1):105–15.

35. Kaneko K, Oono Y, Yano T, et al. Effect of novel bright image enhanced endoscopy using blue laser imaging (BLI). *Endosc Int Open* 2014;2:2512–19.

36. Dohi O, Yagi N, Majima A, et al. Diagnostic ability of magnifying endoscopy with blue laser imaging for early gastric cancer: a prospective study. *Gastric Cancer* 2016.

37. Fugazza A, Gaiani F, Carra MC, et al. Confocal laser endomicroscopy in endoscopic tri-modal imaging endoscopy after endoscopic submucosal dissection for superficial gastric neoplasia. *J Gastroenterol Hepatol* 2014;19:4221–9.

38. Lim LG, Yeoh KG, Srivastava S, et al. Comparison of probe-based confocal endomicroscopy with virtual chromoendoscopy and White-light endoscopy for diagnosis of gastric intestinal metaplasia. *Surg Endosc* 2013;27:6495–59.

39. Lim LG, Yeoh KG, Salto-Tellez M, et al. Experienced versus inexperienced endoscopists in the diagnosis of gastric adenocarcinoma and intestinal metaplasia on confocal images. *Gastrointest Endosc* 2011;73:1141–7.

40. Pitayanon R, Rerknimitr R, Wisedopas N, et al. The learning curve of gastric intestinal metaplasia interpretation on the images obtained by probe-based confocal laser endomicroscopy. *Diagn Ther Endosc* 2012;2012:278045.

41. Kobayashi M, Neumann H, Hino S, et al. Influence of reviewers’ clinical backgrounds on interpretation of confocal laser endomicroscopy findings. *Endoscopy* 2016;48:521–9.

42. Kaise M, Ohkura Y, Izuka T, et al. Endocytoscopy is a promising modality with high diagnostic accuracy for gastric cancer. *Endoscopy* 2015;47:19–25.

43. Sato H, Inoue H, Hayee B, et al. In vivo histopathology using endocytoscopy for non-neoplastic changes in the gastric mucosa: a prospective pilot study (with video). *Gastrointest Endosc* 2015;81:875–81.

44. Teh SK, Zheng W, Ho KY, et al. Near-infrared Raman spectroscopy for optical diagnosis in the stomach: identification of Helicobacter-pylori infection and intestinal metaplasia. *Int J Cancer* 2010;126:1920–7.

45. Bergholt MS, Zheng W, Ho KY, et al. Fiber-optic Raman spectroscopy probes gastric carcinogenesis in vivo at endoscopy. *J Biophotonics* 2013;6:49–59.

46. Teh SK, Zheng W, Ho KY, et al. Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach. *Br J Surg* 2010;97:550–7.

47. Kawabata T, Kikuchi H, Okazaki S, et al. Near-infrared multichannel Raman spectroscopy with a 1064 nm excitation wavelength for ex vivo diagnosis of gastric cancer. *J Surg Res* 2011;169:147–53.

48. Bergholt MS, Zheng W, Lin K, et al. Raman endoscopy for in vivo differentiation between benign and malignant ulcers in the stomach. * Analyst* 2010;135:3162–8.

49. Tang J, Wang L, Song L, et al. Roles of linear and circular polarization properties and effect of wavelength choice on differentiation between ex vivo normal and cancerous gastric samples. *J Biomed Opt* 2014;19:046020.

50. Wang W, Lim LG, Srivastava S, et al. Investigation on the potential of Mueller matrix imaging for digital staining. *J Biophotonics* 2016;9:364–75.